Olimel N12 (Valine, Alanine, Arginine, Histidine, Isoleucine, Leucine, Methionine, Phenylalanine, Proline, Serin)

The blend supplies a balanced profile of essential and non‑essential amino acids that enter the bloodstream directly. Cells take up these amino acids for protein synthesis, supporting tissue repair, immune function, and maintaining plasma oncotic pressure while bypassing the gastrointestinal tract.

The dose of Olimel N12 is individualized by the prescribing clinician based on the patient’s weight, metabolic status, renal and hepatic function, and overall nutritional goals. The prescriber determines the infusion rate and total daily amount required for each patient.

Safety data for Olimel N12 in pregnancy and lactation are limited. It should only be used when clearly needed and when the potential benefits outweigh any potential risks to the mother or fetus. Clinicians should consult current guidelines and consider alternative nutrition strategies when possible.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required) and import documentation.

Olimel N12 offers a comprehensive amino‑acid profile similar to other commercial amino‑acid solutions but is distinguished by its EU‑origin formulation and compliance with GMP standards. Compared with lipid‑based or mixed‑substrate parenteral formulas, it focuses solely on amino‑acid provision, allowing clinicians to combine it with separate carbohydrate and lipid modules as needed.

Olimel N12 should be stored at 2‑8°C, protected from light, and kept in its original container. Do not freeze or shake the solution. Before use, allow the product to reach room temperature if required by the administration protocol.

Olimel N12 is administered intravenously, typically via a central or peripheral venous catheter. The infusion rate is set according to the prescribing clinician’s orders, and the solution is delivered over a controlled period to minimize infusion‑related reactions.

Serious risks include severe hypersensitivity reactions such as anaphylaxis, hyperammonemia, metabolic acidosis, and significant electrolyte disturbances. Continuous monitoring during infusion helps detect these events early, allowing prompt intervention.

Patients with known hypersensitivity to any component of the formulation, uncontrolled severe electrolyte imbalances, or those at high risk for hyperammonemia should not receive Olimel N12 unless the benefits clearly outweigh the risks and appropriate monitoring is in place.